Hexokinase inhibitors are a class of chemical compounds designed to specifically target and inhibit the activity of hexokinase, a key enzyme in the glycolytic pathway. Hexokinase catalyzes the first step in glycolysis by phosphorylating glucose to glucose-6-phosphate, a crucial process for glucose metabolism in cells. Inhibiting hexokinase activity disrupts this fundamental step, effectively reducing the rate of glycolysis and subsequent production of energy in the form of ATP. Hexokinase is also known to associate with mitochondria, and its inhibition can interfere with the enzyme's role in regulating metabolic pathways, apoptosis, and mitochondrial function. The ability of hexokinase inhibitors to block this enzyme makes them valuable tools for investigating cellular metabolism and energy production in various biological systems.
In research, hexokinase inhibitors are employed to explore the metabolic adaptations and consequences of glycolytic inhibition in cells. These inhibitors are particularly useful in studying the metabolic flexibility of cells, especially in understanding how they respond to changes in glucose availability or glycolytic flux. By blocking hexokinase activity, researchers can examine shifts in alternative metabolic pathways, such as oxidative phosphorylation or fatty acid oxidation, providing insights into cellular energy homeostasis and adaptability. Additionally, hexokinase inhibitors can shed light on the regulation of glucose metabolism in different tissues and organisms, facilitating studies on the role of metabolic enzymes in maintaining cellular function under various physiological and environmental conditions. These inhibitors offer a powerful approach to probing the complex interactions between metabolism, cellular signaling, and energy regulation.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
2-Deoxy-D-glucose | 154-17-6 | sc-202010 sc-202010A | 1 g 5 g | $70.00 $215.00 | 26 | |
This glucose analog is phosphorylated by hexokinase but cannot undergo further metabolism, thus competing with glucose and inhibiting its conversion to glucose-6-phosphate. | ||||||
N-Acetyl-D-glucosamine | 7512-17-6 | sc-286377 sc-286377B sc-286377A | 50 g 100 g 250 g | $94.00 $162.00 $306.00 | 1 | |
Acts as a competitive inhibitor by binding to the enzyme's active site, preventing glucose from being phosphorylated. | ||||||
Lonidamine | 50264-69-2 | sc-203115 sc-203115A | 5 mg 25 mg | $105.00 $364.00 | 7 | |
Binds specifically to hexokinase II, disrupting its interaction with the mitochondrial voltage-dependent anion channel and inhibiting its enzymatic activity. | ||||||
D-(−)-Fructose | 57-48-7 | sc-221456 sc-221456A sc-221456B | 100 g 500 g 5 kg | $41.00 $91.00 $166.00 | 3 | |
Serves as a substrate for hexokinase but with a much lower affinity than glucose; can compete with glucose when present in high amounts. | ||||||
D-Glucosamine | 3416-24-8 | sc-278917A sc-278917 | 1 g 10 g | $201.00 $779.00 | ||
Acts as a competitive inhibitor by binding to the enzyme's active site, preventing glucose from undergoing phosphorylation. | ||||||
Rosiglitazone | 122320-73-4 | sc-202795 sc-202795A sc-202795C sc-202795D sc-202795B | 25 mg 100 mg 500 mg 1 g 5 g | $120.00 $326.00 $634.00 $947.00 $1259.00 | 38 | |
Though primarily an antidiabetic drug, it can modulate hexokinase activity indirectly through its effects on cellular glucose uptake and utilization. | ||||||